Electronic structure and interfacial features of triphenylamine- and phenothiazine-based hole transport materials for methylammonium lead iodide perovskite solar cells.

Recently, great research efforts have been devoted to perovskite solar cells (PSCs) leading to sunlight-to-power conversion efficiencies above 25%. However, several barriers still hinder the full deployment of these devices. Critical issues are related to PCE stability and device lifetimes, which could be improved by targeted engineering of the hole transport material (HTM). Indeed, the HTM is not only responsible for transporting holes and preventing direct contact between the photo-active perovskite and the charge collector layer, but it plays important structural and protective roles too. As alternatives to the widely used yet expensive and unstable Spiro-OMeTAD, organic HTMs based on triphenylamine (TPA) and phenothiazine (PTZ) moieties have been proposed. However, their performances in PSC devices, and in particular their interfacial properties with the most popular methylammonium lead iodide perovskite (MAPI) still need investigations to be fully determined. In this framework, here we report a first-principles study on the structural and the electronic properties of a recently designed TPA and PTZ-based HTM (HTM1) and its interface with the MAPI (001) surface, considering both the PbI2- and the MAI-terminations. We also addressed already known HTM molecular systems to allow for a direct comparison with the recently proposed HTM1: we characterized the molecular parameters and the MAPI/HTM interfacial properties for Spiro-OMeTAD, PTZ1, and PTZ2. Our results suggest that good adhesion properties do not ensure effective and efficient MAPI-HTM hole injection. Despite the theoretical good alignment between HTM1 HOMO and MAPI valence band edge, our results for the mutually polarized interface point out the lack of a sufficient driving force for hole transport. While the hole mobility of HTM1 outperforms those of the other HTM molecules, for this HTM molecule, our findings suggest the application of lead halide perovskite compositions other than MAPI, with substituents that lower its valence band maximum potential value.

Synthesis and Characterization of New Organic Dyes Containing the Indigo Core.

A new series of symmetrical organic dyes containing an indigo central core decorated with different electron donor groups have been prepared, starting from Tyrian Purple and using the Pd-catalyzed Stille-Migita coupling process. The effect of substituents on the spectroscopic properties of the dyes has been investigated theoretically and experimentally. In general, all dyes presented intense light absorption bands, both in the blue and red regions of the visible spectrum, conferring them a bright green color in solution. Using the same approach, an asymmetrically substituted D-A-π-A green dye, bearing a triarylamine electron donor and the cyanoacrylate acceptor/anchoring group, has been synthesized for the first time and fully characterized, confirming that spectroscopic and electrochemical properties are consistent with a possible application in dye-sensitized solar cells (DSSC).

Orange/Red Benzo[1,2-b:4,5-b']dithiophene 1,1,5,5-Tetraoxide-Based Emitters for Luminescent Solar Concentrators: Effect of Structures on Fluorescence Properties and Device Performances.

Luminescent solar concentrators (LSCs) are a class of optical devices able to harvest, downshift, and concentrate sunlight, thanks to the presence of emitting materials embedded in a polymer matrix. Use of LSCs in combination with silicon-based photovoltaic (PV) devices has been proposed as a viable strategy to enhance their ability to harvest diffuse light and facilitate their integration in the built environment. LSC performances can be improved by employing organic fluorophores with strong light absorption in the center of the solar spectrum and intense, red-shifted emission. In this work, we present the design, synthesis, characterization, and application in LSCs of a series of orange/red organic emitters featuring a benzo[1,2-b:4,5-b']dithiophene 1,1,5,5-tetraoxide central core as an acceptor (A) unit. The latter was connected to different donor (D) and acceptor (A') moieties by means of Pd-catalyzed direct arylation reactions, yielding compounds with either symmetric (D-A-D) or non-symmetric (D-A-A') structures. We found that upon light absorption, the compounds attained excited states with a strong intramolecular charge-transfer character, whose evolution was greatly influenced by the nature of the substituents. In general, symmetric structures showed better photophysical properties for the application in LSCs than their non-symmetric counterparts, and using a donor group of moderate strength such as triphenylamine was found preferable. The best LSC built with these compounds presented photonic (external quantum efficiency of 8.4 ± 0.1%) and PV (device efficiency of 0.94 ± 0.06%) performances close to the state-of-the-art, coupled with a sufficient stability in accelerated aging tests.

Prolonged-Release Buprenorphine Therapy in Opioid Use Disorder Can Address Stigma and Improve Patient Quality of Life.

Treatment for opioid use disorder (OUD) including opioid agonist therapy (OAT) is effective. Medication with the oral administration of methadone and buprenorphine has well-known limitations (establishing consistent optimal dosing levels, misuse, diversion, and accidental exposure). Treatment may require attendance at treatment services for collection and consumption of medication; this is associated with stigma and discrimination. Novel therapeutic options include approved, injectable, prolonged-release buprenorphine (PRB) products providing consistently optimal drug levels and less frequent dosing. This work assesses the lived experience of persons currently engaged in OUD therapy to define the potential value of novel therapeutic options in order to inform treatment decisions. One hundred and twenty-two people engaged with treatment services participated in this assessment. Seventy-two percent of participants believed that novel therapeutic options would improve quality of life and 67% stated it would reduce stigma and discrimination. Participants were neither concerned about the efficacy of (net score negative 30%), or lack of control over (net score negative 36%) treatment, nor about reduced contact with treatment services (net score negative 11%). Results from this assessment indicate that the provision of choice including novel therapeutic options is likely to improve quality of life and reduce the stigma of persons with OUD.